Cargando…
Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Epidemiological evidence suggests that by the age of 40 years, all individuals with Down syndrome (DS) have Alzheimer’s disease (AD) neuropathology. Clinical diagnosis of dementia by cognitive assessment is complex in these patients due to the pre-existing and varying intellectual disability, which...
Autores principales: | Montoliu-Gaya, Laia, Strydom, Andre, Blennow, Kaj, Zetterberg, Henrik, Ashton, Nicholas James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397053/ https://www.ncbi.nlm.nih.gov/pubmed/34441934 http://dx.doi.org/10.3390/jcm10163639 |
Ejemplares similares
-
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019) -
Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021) -
The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018) -
Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022) -
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)